​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $862.74, with a high of $1,057.00 and a low of $700.00. This represents a 15.55% increase from the last price of $746.61.

$700 $800 $900 $1 $1 $1 High: $1057 Avg: $862.74 Low: $700 Last Closed Price: $746.61

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (70.83%), 14 Hold (29.17%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 14 34 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals15.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31645
Avg Price Target$835.33$855.69$790.60
Last Closing Price$746.61$746.61$746.61
Upside/Downside11.88%14.61%5.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 262178--27
Feb, 262178--27
Jan, 262148-125
Dec, 253167-127
Nov, 254155-125
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Greg RenzaTruist Financial$818.00$770.326.19%9.56%
Mar 06, 2026Eliana MerleBarclays$923.00$764.9320.66%23.63%
Mar 02, 2026Brian AbrahamsRBC Capital$765.00$784.06-2.43%2.46%
Feb 09, 2026Guggenheim$975.00$785.5124.12%30.59%
Feb 02, 2026Carter GouldCantor Fitzgerald$800.00$757.595.60%7.15%
Feb 02, 2026Brian SkorneyRobert W. Baird$742.00$755.34-1.77%-0.62%
Feb 02, 2026Oppenheimer$865.00$741.4516.66%15.86%
Feb 01, 2026Terence FlynnMorgan Stanley$769.00$741.453.72%3.00%
Jan 30, 2026Raymond James$870.00$741.4517.34%16.53%
Jan 27, 2026William PickeringTudor Pickering$916.00$762.1020.19%22.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 09, 2026Cowen & Co.BuyBuyhold
Mar 06, 2026BarclaysOverweightOverweightinitialise
Mar 02, 2026RBC CapitalSector PerformSector Performhold
Feb 24, 2026JefferiesHoldHoldhold
Feb 09, 2026GuggenheimBuyBuyhold
Feb 02, 2026BMO CapitalOutperformOutperformhold
Feb 02, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 02, 2026OppenheimerOutperformOutperformhold
Jan 30, 2026Raymond JamesOutperformOutperformhold
Jan 29, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$30 $40 $50 $60 $70 $80 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.40$40.51$37.05$40.90$43.07---
Avg Forecast$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %6.82%-4.91%-13.07%-9.15%-3.24%---

Revenue Forecast

$11B $13B $15B $16B $18B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.07B$12.17B$13.12B$14.20B$14.34B---
Avg Forecast$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %2.39%2.62%1.37%0.15%-1.95%---

Net Income Forecast

$3B $4B $5B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.08B$4.34B$3.95B$4.41B$4.50B---
Avg Forecast$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %10.75%-3.36%--14.28%3.36%---

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 14 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 48 Wall Street analysts, averages $862.74 over the next 12 months. The price target range spans from $700 at the low end to $1.06K at the high end, suggesting a potential 15.55% change from the previous closing price of $746.61.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 15.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • March 2026: 7.41% Strong Buy, 62.96% Buy, 29.63% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 7.41% Strong Buy, 62.96% Buy, 29.63% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 8.00% Strong Buy, 56.00% Buy, 32.00% Hold, 0% Sell, 4.00% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $48.41, marking a 12.40% increase from the reported $43.07 in 2025. Estimates for the following years are $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $15.52B, reflecting a 8.21% increase from the reported $14.34B in 2025. The forecast for 2027 is $17.22B, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.65B, representing an 3.12% increase from the reported $4.5B in 2025. Projections indicate $5.3B in 2027, and $6.95B in 2028.